Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration-Reference-Cited by-同舟云学术

Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration

Published:2020 Issue:11 Volume:67 Page:1127-1138
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Isshiki Masashi¹,Sakuma Ichiro²,Hayashino Yasuaki³,Sumita Takashi⁴,Hara Kazuo⁵,Takahashi Kazuhisa⁶,Shiojima Ichiro⁶,Satoh-Asahara Noriko⁷,Kitazato Hiroji⁸,Ito Daisuke¹⁴,Saito Daigo¹⁴,Hatano Masako¹,Ikegami Yuichi¹,Iida Shinichiro⁹,Shimada Akira¹,Noda Mitsuhiko¹¹⁰

Affiliation:

1. Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan

2. Caress Sapporo Hokko Memorial Clinic, Hokkaido 065-0027, Japan

3. Department of Endocrinology, Tenri Hospital, Nara 632-8552, Japan

4. Department of Endocrinology and Diabetes, Japanese Red Cross Ogawa Hospital, Saitama 355-0397, Japan

5. Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, Saitama 330-8503, Japan

6. Department of Medicine II, Kansai Medical University, Osaka 573-1191, Japan

7. Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan

8. Division of Diabetes and Endocrinology, Japanese Red Cross Omori Hospital, Tokyo 143-8527, Japan

9. Department of General Internal Medicine, Saitama Medical University Hospital, Saitama 350-0495, Japan

10. Department of Diabetes, Metabolism and Endocrinology, Ichikawa Hospital, International University of Health and Welfare, Chiba 272-0827, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/67/11/67_EJ20-0222/_pdf

Reference32 articles.

1. 1 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128.

2. 2 Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657.